COCP - Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19
- Cocrystal Pharma ( NASDAQ: COCP ) on Tuesday said it had selected its antiviral drug candidate CDI-988 for clinical development as an oral treatment for COVID-19.
- Shares of the micro-cap clinical-stage biotech fell 7.2% to $2.55 in premarket trading.
- CDI-988 targets a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral replication, COCP said in a statement .
- Once investigational new drug application-enabling toxicology studies for CDI-988 are completed, the company plans to file for regulatory approval to begin a human trial in Australia in Q1 2023.
For further details see:
Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19